Long-Term Epidemiology of Streptococcus pneumoniae Serogroup 6 in a Region of Southern Europe with Special Reference to Serotype 6E

José M Marimón; María Ercibengoa; Esther Tamayo; Marta Alonso; Emilio Pérez-Trallero

doi:10.1371/journal.pone.0149047

Long-Term Epidemiology of Streptococcus pneumoniae Serogroup 6 in a Region of Southern Europe with Special Reference to Serotype 6E

PLoS One. 2016 Feb 10;11(2):e0149047. doi: 10.1371/journal.pone.0149047. eCollection 2016.

Authors

José M Marimón^{1

2}, María Ercibengoa², Esther Tamayo², Marta Alonso¹, Emilio Pérez-Trallero^{1

2

3}

Affiliations

¹ Microbiology Department, Hospital Universitario Donostia-Instituto Biodonostia, San Sebastián, Spain.
² Biomedical Research Center Network for Respiratory Diseases (CIBERES), San Sebastián, Spain.
³ Faculty of Medicine, University of the Basque Country, UPV/EHU, San Sebastián, Spain.

Abstract

Streptococcus pneumoniae serotype 6E has recently been described, but its long-term epidemiology is not well known. From 1981-2013, 704 serogroup 6 clinical isolates were obtained in Gipuzkoa, Basque Country, Spain. All invasive and one in four non-invasive isolates were included. Overall, 75, 97, 51 and 45 serotypes 6A, 6B, 6C and 6E isolates, respectively, were detected. No serotype 6D isolates were identified. The prevalence of serotypes 6E and 6B, but not that of serotypes 6A and 6C, declined after the introduction of pneumococcal conjugate vaccines. Serotype 6E isolates showed the highest resistance rate. Most serotype 6E isolates were ST90.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Child
Child, Preschool
Drug Resistance, Bacterial
Europe
Female
Genotype
Humans
Infant
Infant, Newborn
Male
Microbial Sensitivity Tests
Middle Aged
Pneumococcal Infections / epidemiology*
Pneumococcal Infections / microbiology*
Pneumococcal Vaccines
Prevalence
Retrospective Studies
Serogroup
Serotyping
Spain
Streptococcus pneumoniae / classification*
Young Adult

Substances

Pneumococcal Vaccines

Grants and funding

This work was partially financed by the grant IT656/13 from the Basque Country Government's Department of Education, Universities and Research and from the grant PI 13/01708 (http://www.hezkuntza.ejgv.euskadi.eus/r43-2591/es) and Fondo de Investigaciones Sanitarias-Health Research Fund, Instituto de Salud Carlos III, Spanish Ministry of Health, Social Services and Equality (http://www.isciii.es/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.